Jason Roszik

Aug 28, 2024 | digitalcommons.library.tmc.edu | Fan Fan |Susmita Ghosh |Reid T. Powell |Jason Roszik

AbstractMetastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concentrated on targeting MEK, a downstream mediator of RAS. However, targeting MEK as single-agent therapy is ineffective in patients with mCRC.